The firm served as lead counsel for Biotec Pharmacon, ASA, a Norwegian pharmaceutical company, in patent infringement litigation initiated by patent owner Biothera, a Minnesota corporation, in the District of Minnesota in Minneapolis. The 14 patents involved in the litigation relate to, among other things, beta glucan compositions for immunotherapy. The District Court granted summary judgment of non-infringement as to 12 of the 14 patents, and the case subsequently settled.

Biopolymer Eng'g, Inc. v. Immunocorp, No. 05-536 (D. Minn. filed Mar. 14, 2005).

Experience Center

Match our Experience to Your Needs

Experience Highlights

Acquisition for a developer of commercial and residential properties
The firm served as lead counsel in the acquisition for a developer of commercial and residential properties. more
Private investments for a major institutional investor
Represented a major institutional investor in connection with over 30 investments, with an aggregate value of nearly $3 billion, in various private more
Obtaining various regulatory exemptions for a benefits payment services company
Represented a benefits payment services company in obtaining exemptions from the HIPAA electronic transaction rule. more
Large community-owned utility matter
Represented one of the largest community-owned utility in the United States, in a matter involving defectively constructed runways that ultimately more